Wednesday, June 10, 2026

pharma Β· Body weight management Β· Acromegaly

Currus Biologics Pty

Currus Biologics Pty drug portfolio β€” 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Melbourne, AU HQ
2021 Founded
11 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2021
Employees
11
Programs
3
Drugs
14
Patents
0
Intelligence Β· Drug Pipeline

Currus Biologics Pty pipeline

Portfolio lens on 14 drugs and development assets β€” regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Currus Biologics Pty drug portfolio β€” 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

14 compounds
  1. US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown
  2. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  3. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  4. Development asset linked to Currus Biologics Pty in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.

    Mechanism
    Somatostatin receptor 2 agonist
  5. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  6. octreotide

    Systemic hormonal preparations (H01)

    Systemic hormonal preparations (H01) compound in Currus Biologics Pty's portfolio. Mechanism: Somatostatin receptor agonist.

    Mechanism
    Somatostatin receptor agonist
  7. US regulatory status: approved. Molecular target: Somatostatin receptor.

    Target
    Somatostatin receptor
    Mechanism
    Somatostatin receptor agonist
  8. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  9. semaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist
  10. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  11. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  12. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  13. Development asset linked to Currus Biologics Pty in public FDA and regional records.

  14. Development asset linked to Currus Biologics Pty in public FDA and regional records.